# GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Atypical Hyperplasia Patients

> **NCT06390904** · PHASE2,PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Xiaojun Chen** · enrollment: 29 (estimated)

## Conditions studied

- Atypical Endometrial Hyperplasia
- Progesterone Resistance
- Obesity

## Interventions

- **DRUG:** GnRH antagonist
- **DRUG:** Letrozole 2.5mg

## Key facts

- **NCT ID:** NCT06390904
- **Lead sponsor:** Xiaojun Chen
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-07-13
- **Primary completion:** 2025-07-30
- **Final completion:** 2027-07-30
- **Target enrollment:** 29 (ESTIMATED)
- **Last updated:** 2025-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06390904

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06390904, "GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Atypical Hyperplasia Patients". Retrieved via AI Analytics 2026-06-11 from https://api.ai-analytics.org/clinical/NCT06390904. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*